SAGE Therapeutics (NASDAQ:SAGE) Price Target Lowered to $100.00 at Royal Bank of Canada

Share on StockTwits

SAGE Therapeutics (NASDAQ:SAGE) had its target price trimmed by Royal Bank of Canada from $190.00 to $100.00 in a report released on Friday morning, Briefing.com Automated Import reports. The firm currently has an outperform rating on the biopharmaceutical company’s stock.

SAGE has been the subject of a number of other research reports. ValuEngine raised shares of SAGE Therapeutics from a buy rating to a strong-buy rating in a report on Thursday, December 5th. Piper Jaffray Companies dropped their price objective on shares of SAGE Therapeutics from $206.00 to $125.00 and set an overweight rating on the stock in a report on Thursday, December 5th. SunTrust Banks downgraded SAGE Therapeutics from a buy rating to a hold rating and cut their target price for the company from $210.00 to $70.00 in a research report on Thursday, December 5th. Morgan Stanley reduced their target price on SAGE Therapeutics from $217.00 to $125.00 and set an overweight rating for the company in a research note on Friday. Finally, BidaskClub raised SAGE Therapeutics from a strong sell rating to a sell rating in a research report on Thursday, November 21st. One research analyst has rated the stock with a sell rating, six have issued a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. SAGE Therapeutics presently has an average rating of Buy and an average price target of $128.81.

Shares of SAGE Therapeutics stock opened at $62.66 on Friday. The company has a 50 day moving average price of $137.72 and a 200 day moving average price of $159.26. The firm has a market capitalization of $3.34 billion, a P/E ratio of -7.75 and a beta of 2.52. The company has a quick ratio of 12.67, a current ratio of 12.67 and a debt-to-equity ratio of 0.03. SAGE Therapeutics has a 52 week low of $56.50 and a 52 week high of $193.56.

SAGE Therapeutics (NASDAQ:SAGE) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($3.48) earnings per share for the quarter, missing the consensus estimate of ($3.41) by ($0.07). SAGE Therapeutics had a negative return on equity of 60.00% and a negative net margin of 12,931.34%. The company had revenue of $3.57 million for the quarter, compared to analysts’ expectations of $2.52 million. During the same period in the prior year, the firm posted ($2.63) EPS. The firm’s revenue for the quarter was up 35600.0% on a year-over-year basis. As a group, research analysts anticipate that SAGE Therapeutics will post -13.77 earnings per share for the current fiscal year.

Several large investors have recently added to or reduced their stakes in the company. Invesco Ltd. lifted its position in SAGE Therapeutics by 197.2% during the second quarter. Invesco Ltd. now owns 2,021,964 shares of the biopharmaceutical company’s stock valued at $370,201,000 after purchasing an additional 1,341,720 shares during the period. Nuveen Asset Management LLC acquired a new stake in SAGE Therapeutics during the 2nd quarter worth about $113,776,000. Jennison Associates LLC raised its stake in shares of SAGE Therapeutics by 25.4% during the 2nd quarter. Jennison Associates LLC now owns 2,953,913 shares of the biopharmaceutical company’s stock valued at $540,832,000 after buying an additional 598,299 shares during the last quarter. Janus Henderson Group PLC raised its stake in shares of SAGE Therapeutics by 12.3% during the 2nd quarter. Janus Henderson Group PLC now owns 1,873,408 shares of the biopharmaceutical company’s stock valued at $343,002,000 after buying an additional 204,779 shares during the last quarter. Finally, State Street Corp raised its stake in shares of SAGE Therapeutics by 8.8% during the 3rd quarter. State Street Corp now owns 1,039,599 shares of the biopharmaceutical company’s stock valued at $145,845,000 after buying an additional 84,138 shares during the last quarter.

About SAGE Therapeutics

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).

Further Reading: How is the Producer Price Index calculated?

Analyst Recommendations for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.